npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers420
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer208
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab179
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer160
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer147
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?110
International survey on invasive lobular breast cancer identifies priority research questions107
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab103
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients96
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women85
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer80
Biological correlates associated with high-risk breast cancer patients identified using a computational method78
Immunotherapy for early triple negative breast cancer: research agenda for the next decade78
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells72
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors70
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment69
Breastfeeding attributable fraction of triple negative breast cancer in the US64
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)62
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer57
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events56
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models54
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer51
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer50
Temporal evolution of breast cancer brain metastases treatments and outcomes49
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial46
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer46
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice45
Survival outcomes after omission of surgery for ductal carcinoma in situ44
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)44
Circulating tumor DNA validity and potential uses in metastatic breast cancer42
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays39
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC38
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer38
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases38
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis37
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines37
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer36
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer36
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors33
Kataegis in clinical and molecular subgroups of primary breast cancer32
Understanding metastasis mixed-treatment responses through genomic analyses32
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center32
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification31
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer31
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment30
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer29
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance29
Is conservative management of ductal carcinoma in situ risky?29
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models29
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201629
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer28
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program28
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies27
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
Large language model (ChatGPT) as a support tool for breast tumor board26
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer26
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin26
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer25
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer25
A systematic review of determinants of breast cancer risk among women with benign breast disease25
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study24
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer24
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy24
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial24
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies23
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief23
Prognostic value of structural variants in early breast cancer patients22
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer21
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape20
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women20
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer19
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer18
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor18
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women18
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer17
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry17
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer17
Subclonal heterogeneity and evolution in breast cancer17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study16
Racial discrimination among women seeking breast cancer care16
Plasma C-peptide mammographic features and risk of breast cancer16
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
Artificial intelligence in breast pathology – dawn of a new era16
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Genomic landscape of breast cancer in elderly patients15
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Advancing equitable access to innovation in breast cancer15
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
0.08440899848938